Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats

Bayer pushes stroke prevention drug forward in China as regulators accept key filing

Stroke is the second-leading cause of death and the third-leading cause of disability worldwide

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke

Bayer’s experimental stroke drug could reshape secondary stroke prevention

Millions of stroke survivors across the world may soon have a new defense

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.

Translumina launches Dual-Drug Polymer-free Coated Stent (DDCS)

Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey